ETEric Thouvenot

Eric Thouvenot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric Thouvenot has a total of 841 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clear Positive MOG Antibodies in Adults With Multiple Sclerosis Features

    by Jeanne Garcia, Natalia Shor, Clemence Boutiere, Julie Pique, Marine Boudot De La Motte, Maxime Guillaume, Adrien Delourme, Helene Zephir, Jonathan Ciron, Clarisse Carra-Dalliere, et al.

    Distinguishing multiple sclerosis (MS) from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can be challenging because of some shared clinical and radiologic features. We aimed to describe adults with clear positive serum MOG antibodies (MOG-Abs) presenting with MS features and rethink their nosological framework. We conducted a retrospective longitudinal study within the French NOMADMUS cohort and included adults from 2015 to 2025 tested clear positive for MOG-Ab in the serum with at least 1 MS-suggestive feature: (1) biological (CSF-specific oligoclonal bands [OCBs] and/or kappa free light chain index [KFLCi] ≥5.7) or (2) radiologic (≥1 lesion among juxtacortical lesion, Dawson finger, or inferior temporal lobe lesion). All MRI scans were reviewed blindly by an expert neuroradiologist. Minimum clinical and radiologic follow-up was 6 months. We classified patients as (1) typical MS when fulfilling 2024 McDonald criteria, with OCB and/or KFLCi ≥5.7 and showing no MOGAD supporting features, or (2) equivocal in all other situations. Among the 78 included patients (65% female, median age: 35 years), 23% were classified as typical MS and 77% as equivocal; all met MOGAD criteria, and 76% met 2024 McDonald criteria, without using central veinous sign or paramagnetic rim lesion, which have been rarely assessed. Myelitis followed by optic neuritis constituted the predominant clinical presentations in the whole cohort (45% and 32%, respectively) and in both groups. For typical MS cases, half of the patients did not receive maintenance therapy after the first MOG-Ab-positive event, 28% relapsed, 55% developed new silent lesions, and none showed lesion resolution (median follow-up: 1.9 years). For equivocal patients, 84% had OCB and 88% had ≥1 MOGAD supporting feature. After the first MOG-Ab-positive event, 72% initiated a maintenance therapy-mostly rituximab-15% relapsed, 46% developed silent new lesions, and 23% showed complete resolution of ≥1 lesion (median follow-up: 3 years). Clear positive MOG-Ab may occur in patients with genuine MS, and their presence may lead to therapeutic inertia. The substantial proportion of equivocal cases highlights current diagnostic limitations and underscores the need for longitudinal clinical and radiologic reassessment.

  • Open Access

    APOLLAI, a multimodal AI system, versus EMS personnel for prehospital detection of stroke-related deficits

    by Cédric Javault, Estefania Vargas Gonzalez, Lionel Pibre, Félix Yriarte, Eric Thouvenot

    Background and Purpose: Prehospital stroke recognition remains suboptimal, with nearly one-third of strokes unidentified before hospital arrival, and neurological assessment being inherently subjective, with substantial interobserver variability even among certified clinicians. APOLLAI, a multimodal artificial intelligence system, was developed to detect stroke-related neurological deficits from video and audio recordings. We compared the diagnostic performance of APOLLAI and emergency medical services (EMS) personnel against an expert consensus reference standard. Methods: In this prospective study, video recordings of 295 patients with suspected stroke (mean age, 70.3±13.3 years) were obtained at Nîmes University Hospital (August 2023–July 2025). Five National Institutes of Health Stroke Scale items (best gaze, facial palsy, motor arm, aphasia, dysarthria) were independently annotated by seven certified stroke neurologists, combined into consensus labels using the Dawid–Skene algorithm, and separately assessed by EMS personnel (mean of 15 raters per patient). APOLLAI, a multimodal machine-learning framework that combines computer vision, audio-based deep learning, and a final support vector machine (SVM) fusion classifier, was evaluated against EMS using sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC). Results: Interrater agreement among the seven neurologists was moderate overall (mean κ=0.541; range, 0.367–0.732), indicating an intrinsic difficulty of neurological assessment. APOLLAI showed higher sensitivity than EMS for all five neurological tasks and for the global assessment (78.5% versus 59.4%), with broadly comparable specificity (87.0% versus 85.9% for the global assessment). AUC values ranged from 0.839 (facial palsy) to 0.966 (best gaze), with a global AUC of 0.882. Conclusions: APOLLAI demonstrated higher sensitivity than EMS personnel for detecting stroke-related neurological deficits, with preserved specificity. These findings support its potential as a standardized, scalable adjunct to prehospital stroke recognition, warranting prospective validation under real-world EMS conditions.

  • Open Access

    Serum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack

    by Manon Rival, Fabien Rollot, Sabine Laurent‐Chabalier, Romain Casey, Illiasse El Bahi, Guillaume Brocard, Romain Marignier, Sophie Trouillet‐Assant, Sandra Vukusic, Agnès Fromont, et al.

    Background: Serum neurofilament‐light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are associated with multiple sclerosis (MS) activity. This study aimed to identify patient‐ and disease‐level determinants of sNfL and sGFAP and to evaluate their ability to support differential diagnosis in neuromyelitis optica (NMO). Methods: sNFL and sGFAP levels were measured in 640 patients from the OFSEP cohort (88 NMO spectrum disorder (NMOSD) with anti‐aquaporin‐4 antibodies [AQP4‐NMOSD], 28 double‐seronegative NMOSD [DN‐NMOSD], 61 myelin oligodendrocyte glycoprotein antibody–associated disease [MOGAD], 64 clinically isolated syndrome [CIS], 237 relapsing–remitting MS [RRMS], and 162 primary progressive MS [PPMS]). The association between log[sNFL] and log[sGFAP] and age, sex, time since relapse, EDSS, oligoclonal bands, and MRI characteristics was analyzed by multiple linear regression. The diagnostic performance of sNfL and sGFAP in discriminating between NMOSD and MS subgroups was evaluated using multivariable logistic regression and area under the curve (AUC). Results: For each group, specific associations of sNFL and sGFAP levels with patient characteristics were observed. Clearest associations were observed in AQP4‐NMOSD patients. After a recent attack (≤ 90 days), multivariate analysis revealed that sGFAP and age discriminated AQP4‐NMOSD from MOGAD (AUC = 0.939 [0.910;0.982]), AQP4‐NMOSD and DN‐NMOSD from MOGAD (AUC = 0.863 [0.776;0.977]), and AQP4‐NMOSD from all other groups (AUC = 0.950 [0.918;0.987]). Diagnostic probability heatmaps based on sGFAP and age illustrate the probability of each diagnosis relative to others for bedside interpretation. Conclusion: After an acute attack of NMOSD, risk score based on sGFAP and age may guide the management of patients before autoantibody status is available.

  • Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data

    by Chao Zhu, Sandra Vukusic, Tomas Kalincik, Guillaume Mathey, Allan G Kermode, Elisabeth Maillart, Jeannette Lechner-Scott, Emanuelle Le Page, Izanne Roos, Jonathan Ciron, et al.

    Background Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice. Methods We conducted an observational cohort study emulating a target trial using data from the MSBase and Observatoire Français de la Sclérose en Plaques registries (January 2021 to December 2024). Adults with RRMS initiating ofatumumab or ocrelizumab were included. Patients were matched 1:1 using propensity scores. Primary outcomes were annualised relapse rate (ARR) and time to first relapse. Secondary outcomes included time to confirmed disability progression (CDP), progression independent of relapse activity (PIRA), confirmed disability improvement (CDI), MRI activity and treatment discontinuation. Negative binomial and Cox regression models were applied. Results A total of 5288 patients were matched with a median follow-up of 1.2 years for ofatumumab and 1.4 years for ocrelizumab. ARR was 0.07 (95% CI 0.05 to 0.08) with ofatumumab and 0.04 (0.03 to 0.05) with ocrelizumab, corresponding to an ARR ratio of 1.75 (1.43 to 2.13). Ofatumumab was associated with a lower risk of CDP (HR 0.66; 0.49 to 0.87) and PIRA (0.53; 0.39 to 0.73), but a lower probability of CDI (0.76; 0.60 to 0.96). No significant differences were observed in MRI activity or treatment discontinuation. Conclusions Both therapies were highly effective in a large cohort of patients with RRMS, with very low relapse or CDP rates. Ofatumumab was associated with slightly greater disability control, while ocrelizumab more effectively suppressed relapses. These differences were modest, and their clinical relevance requires further evidence and should be interpreted with caution.

  • Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severity

    by Emilie Dugast, Sita Shah, Isabel Vogel, Amandine Loret, Céline Monvoisin, Alexandra Garcia, Cynthia Fourgeux, Victor Gourain, Léo Boussamet, Roberta Amoriello, et al.

    Memory CD8+ T cells are central to multiple sclerosis (MS) and undergo clonal expansion, but disease-associated states remain incompletely defined. By single-cell profiling of circulating memory CD8+ T cells from patients with relapsing–remitting MS, healthy volunteers, and neuroinflammatory controls, we identified an MS-associated cytotoxic subset with NK-like features. These cells increase around relapse activity and belong to an oligoclonal reservoir. In an independent cohort sampled at the first clinical event, an elevated frequency of NK-like CD8+ T cells predicted an aggressive MS course two years later and was associated with a migratory/inflammatory program. Bulk and single-cell RNA-seq confirmed the NK-like transcriptional signature, and functional assays demonstrated TCR-independent cytotoxicity. Immunostaining and spatial transcriptomics revealed enrichment of these cells in MS lesions and a spatial association with macrophages/microglia. Together, our results identify a cytotoxic NK-like CD8+ T-cell subset that links peripheral inflammation to CNS lesions and may serve as an early biomarker of MS severity.

  • French NOMADMUS Cohort Overview

    by Thomas Roux, François-Xavier Lejeune, Romain Casey, Bertrand Audoin, Xavier Ayrignac, Bertrand Bourre, Jonathan Ciron, Mikael Cohen, Nicolas Collongues, Francois Cotton, et al.

    ObjectivesAquaporin 4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare conditio...


  • Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis

    by Antoine Gavoille, Anne Kerbrat, Gilles Edan, Emmanuelle Le Page, Fabien Rollot, Romain Casey, Guillaume Mathey, Bruno Stankoff, Jonathan Ciron, Jerome De Seze, et al.

    The therapeutic strategy for late-onset multiple sclerosis (LOMS) with a relapsing-remitting onset remains unclear, potentially leading to underexposure to disease-modifying therapies (DMTs) compared with adult-onset multiple sclerosis (AOMS). We investigated the differences in DMT use between LOMS and AOMS within the French MS registry at comparable levels of disease severity. This retrospective cohort study used data extracted in December 2024 from the French MS registry on patients with relapsing-remitting onset MS between 1997 and 2023. The primary outcome was the annual probability of receiving a DMT according to age at MS onset, adjusted for disease severity. Secondary outcomes included the annual probability of receiving a highly effective DMT (HEDMT), each DMT separately, having ≥1 EDSS measurement, having ≥1 brain MRI, and DMT initiations and discontinuations. We used a longitudinal logistic model with generalized estimating equations and an inverse-probability-of-censoring weighting. A total of 36,148 were included patients; 26,540 (73.4%) were female, mean age was 33.5 years (SD, 9.7), and 2,308 (6.4%) were aged ≥50 at disease onset. Median follow-up was 10.8 years (interquartile range, 5.6-17.0). Patients with LOMS had a lower annual probability of receiving a DMT compared with patients with AOMS (73.7% vs 83.1%; odds ratio [OR], 0.57 [95% CI 0.52-0.62]). The difference was greater for HEDMT (24.6% vs 44.4%; OR, 0.41 [95% CI 0.36-0.46]). Patients with LOMS were more likely to receive teriflunomide and less likely to receive fumarates, S1PR modulators, natalizumab, or anti-CD20. Clinical and radiologic follow-up did not differ significantly between patients with LOMS and AOMS. The rate of DMT initiation was lower in patients with LOMS (0.13 vs 0.17 initiation per patient-year). Although the proportions of DMT discontinuation were similar (59.7% vs 60.4%, excluding pregnancy-related discontinuations), these discontinuations were more often attributed to a complete discontinuation strategy (27.9% vs 22.3%) and less often to an escalation strategy (9.2% vs 13.8%) in patients with LOMS. At comparable levels of disease severity, patients with LOMS were less likely to be treated with DMTs, particularly HEDMT, than patients with AOMS. This gap was driven both by fewer DMT initiations and more frequent complete discontinuations.

  • Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study

    by Michaël Levraut, Mikael Cohen, Delphine Sterlin, Xavier Ayrignac, Kévin Bigaut, Hélène Zéphir, Jonathan Ciron, Jean-Philippe Camdessanché, Olivier Casez, Thibault Moreau, et al.

    Background: Limited evidence exists on how to use kappa free light chains (κFLCs) and oligoclonal bands (OCBs) in diagnosing intrathecal immunoglobulin synthesis (IgS). Objective: To compare different algorithms to define IgS. Methods: A retrospective analysis of the 2022 French cohort study was conducted. Patients were considered to have IgS if (1) the κFLC index was ⩾6.1, (2) OCB was positive, (3) the κFLC index was ⩾6.1 or OCB was positive, (4) the κFLC index was ⩾20 or OCB was positive, regardless of the κFLC index value, or (5) the κFLC index was ⩾20 or OCB was positive (with OCB tested only when the κFLC index was between 3.5 and 20). People with multiple sclerosis (MS) were compared with controls and with a subgroup of age- and sex-matched MS-mimicking disorders. Results: Of 1531 patients, 675 had MS and 856 were controls (133 MS mimics). Agreement between OCB and κFLC index (⩾6.1) was high (89%). All tested algorithms demonstrated high accuracy in separating groups. Using the sequential approach (5) achieves higher specificity and a significant reduction in OCB testing. Conclusion: Using a simple cut-off point of 6.1 for routine screening is accurate, but testing for OCB when the κFLC index is between 3.5 and 20 increases specificity and should be prospectively studied in challenging cases.


  • Open Access

    Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS

    by Apolline Tournier, Antoine Gavoille, Julie Pique, Michael Levraut, Eléonore Micoud, Elisabeth Maillart, Bertrand Audoin, Sarah Demortiere, Clemence Boutiere, Xavier Ayrignac, et al.

    The differential diagnosis between aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), and multiple sclerosis (MS) can be complex. Kappa free light chain index (KFLC-Index) emerged as an effective biomarker for distinguishing patients with MS from patients with other conditions. The main aim of this study was to assess the diagnostic performance of KFLC-Index in differentiating MOGAD, AQP4-NMOSD, and MS and to compare it with CSF-restricted oligoclonal bands (OCB) performance. We conducted a retrospective case-control study involving 18 French centers through our national NOMADMUS database. Patients were eligible if they received MOGAD or AQP4-NMOSD diagnosis and if OCB status and KFLC-Index levels were available or could be measured retrospectively. As a comparator, we included a group of patients with MS from the Lyon center. We included 303 patients with 140 MOGAD, 37 AQP4-NMOSD, and 126 MS. The sex ratio F/M was 1/1 in the MOGAD group, 5/1 in the NMOSD group, and 4/1 in the MS group. The median age was 38 years in the MOGAD group, 52 in the NMOSD group, and 32 in the MS group. The median KFLC-Index (interquartile range) was the lowest in the MOGAD group (0.60 [0.33-2.09]) with 71% of undetectable CSF-KFLC, intermediate in the NMOSD group (8.85 [3.04-16.78]), and the highest in the MS group (49.90 [16.31-113.39]). KFLC-Index had very good diagnostic performance in differentiating MOGAD from MS (area under the curve [AUC] 0.93, 95% CI 0.9-0.96) with an optimal threshold of 5.7 (95% CI 4.74-6.85), a sensitivity of 0.89 (0.83-0.94), and a specificity of 0.89 (0.83-0.94). KFLC-Index had good performance in differentiating NMOSD from MS (AUC 0.82, 95% CI 0.74-0.88) and MOGAD from NMOSD (AUC 0.77, 95% CI 0.69-0.86). KFLC-Index did not significantly outperformed OCB in separating MOGAD from MS and NMOSD from MS; however, the combination of the 2 tests was more performant than used separately. KFLC-Index is a valuable tool in distinguishing MS from AQP4-NMOSD and MOGAD and provides additional information to that given by OCB. We suggest that KFLC-Index as an additional supporting criterion for the differential diagnosis between MOGAD and MS.